Document is current
Any future updates will be listed below
-
Authors
Zhou, Ke https://orcid.org/0000-0003-1221-0008
Cano-Sancho, German https://orcid.org/0000-0003-4111-4007
Goupille, Caroline https://orcid.org/0000-0002-0177-0926
Bessonneau, Vincent https://orcid.org/0000-0003-3442-5026
Gorrochategui Matas, Eva https://orcid.org/0000-0002-5942-6722
Bobin-Dubigeon, Christine https://orcid.org/0000-0001-8944-3219
Frenel, Jean-Sébastien https://orcid.org/0000-0002-5273-0561
Bellanger, Martine https://orcid.org/0000-0002-1892-8961
-
Funding
Funding for this research was provided by:
French NGO ODYSSEA (ODY2022BCEXPO)
Persévérance Foundation (PER2022BCEXPO)
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 30 August 2026
First Online: 5 September 2026
Declarations
Competing interests: The authors declare no competing interests.
Ethical approval: EPICURE was registered on May 21, 2019 with ClinicalTrials.gov identifier (NCT number) : NCT03958136. All participants signed an informed consent form, and the study has been conducted in accordance with the Declaration of Helsinki. The study was authorized by the ANSM Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) (≠ 2018-A00959-46). The Ethics Committee (CPP-IdF I Paris) approved the study (≠ CPPIDF1-2018- ND40-cat.1).
AI use disclosure statement: No generative AI technologies were used in study conceptualization, data curation, data analysis, software programming, visualization and original drafting. Large language model-based technologies have been used for language quality control in final draft editing.
